Li X-B, Yang Y, Zhang H-Q, Yue W-T, Zhang T-M, Lu B-H, Li J, Liu Z, Wang Q-H, Gao Y, Hu A-M, Zhang H-M, Shi H-L, Hu F-B, Li B-L
Department of Oncology, Beijing Chest Hospital, Capital Medical University, No. 97 Ma Chang, Tongzhou District, Beijing, China.
Eur Rev Med Pharmacol Sci. 2015 Jun;19(12):2231-9.
The prognostic role of phosphatase and tensin homolog (PTEN) in non-small cell lung cancer (NSCLC) has been controversial.
In this study, levels of PTEN expression were investigated in NSCLC patients and their prognostic value in NSCLC was assessed. PTEN expression in tumor tissues from 68 NSCLC patients was analyzed using immunohistochemistry and confocal microscopy. Survival analysis was performed using the log-rank test and Cox proportional hazards regression analysis.
NSCLC patients classified as expressers of high levels of PTEN (n = 46) had better prognoses than those classified as expressers of low levels (mean survival 17.1 versus 12.9 months, log-rank p = 0.038). In patients with adenocarcinoma (AC), high PTEN expression (n = 9) was associated with significantly longer survival than low PTEN expression (mean survival 23.50 versus 15.54 months, log-rank p = 0.043). High levels of PTEN expression resulted in 43% reduction in risk for all NSCLC patients (HR = 0.57, 95% CI: 0.33-0.98, p = 0.041). PTEN expression and clinical stage remained significantly associated with survival after adjustment for age, sex and tumor type (HR = 0.56, 95% CI: 0.32-0.99; p = 0.048; HR = 0.54, 95% CI: 0.36-0.97; p = 0.045). No significant difference in continuous PTEN expression levels was observed among groups with different clinical or pathological characteristics (p > 0.17). When levels of PTEN expression were binarized using the optimal cutpoint, higher levels of PTEN expression were observed in patients with T1/T2 than in those with T3/T4 (80% and 58% respectively, p = 0.049) and in patients with AC than in those with squamous-cell carcinoma (SCC) (78% and 58% respectively, p = 0.08). No significant difference in binarized PTEN expression levels was found among groups with any other clinical/pathologic characteristic (p > 0.28).
Our results suggest that high levels of PTEN expression may be favorable prognostic marker in NSCLC patients.
磷酸酶和张力蛋白同源物（PTEN）在非小细胞肺癌（NSCLC）中的预后作用一直存在争议。
在本研究中，调查了NSCLC患者中PTEN的表达水平，并评估了其在NSCLC中的预后价值。使用免疫组织化学和共聚焦显微镜分析了68例NSCLC患者肿瘤组织中的PTEN表达。采用对数秩检验和Cox比例风险回归分析进行生存分析。
PTEN高水平表达的NSCLC患者（n = 46）比低水平表达的患者预后更好（平均生存期17.1个月对12.9个月，对数秩检验p = 0.038）。在腺癌（AC）患者中，PTEN高表达（n = 9）与生存期显著延长相关，而低表达患者的平均生存期为23.50个月对15.54个月，对数秩检验p = 0.043）。PTEN高表达使所有NSCLC患者的风险降低了43%（风险比=0.57，95%置信区间：0.33 - 0.98，p = 0.041）。在调整年龄、性别和肿瘤类型后，PTEN表达和临床分期仍与生存期显著相关（风险比=0.56，95%置信区间：0.32 - 0.99；p = 0.048；风险比=0.54，95%置信区间：0.36 - 0.97；p = 0.045）。在具有不同临床或病理特征的组中，未观察到PTEN连续表达水平的显著差异（p > 0.17）。当使用最佳切点将PTEN表达水平二值化时，T1/T2期患者的PTEN表达水平高于T3/T4期患者（分别为80%和58%，p = 0.049），AC患者的PTEN表达水平高于鳞状细胞癌（SCC）患者（分别为78%和58%，p = 0.08）。在具有任何其他临床/病理特征的组中，未发现二值化PTEN表达水平的显著差异（p > 0.28）。
我们的结果表明，PTEN高表达可能是NSCLC患者预后良好的标志物。
